

OFFICIAL

;408 654 5831

# 1/ 4



galileopharma

Galileo Pharmaceuticals, Inc.  
5301 Patrick Henry Drive  
Santa Clara, CA 95054  
galileopharma.com

RECEIVED  
CENTRAL FAX CENTER

JAN 02 2004

## Facsimile Transmission

Date: 2 January, 2004

To: Director of the Office of Technology Center 1600  
703-872-9306

From: Michelle Y. Walker  
408 654 5830 x 179 (voice)  
408 654 5831 (fax)

4 Pages

Includes:

Transmittal (2 pages)

IDS Form 1449

Fax cover sheet (1 page)

The information in this facsimile should be treated as confidential and is intended only for the use of the addressee specified above. It should be safeguarded from disclosure to others. If the reader is not the intended recipient, you are hereby notified that retention, verbal disclosure, copying, or otherwise disseminating this information is strictly forbidden by federal, state and local law. If you receive this fax in error, please notify the sender and return all copies to the address above.

+  
CERTIFICATE OF MAILING

I hereby certify that this paper is being sent via facsimile to the United States Patent & Trademark Office, FAX# 703-872-9306, on January 2, 2004.

  
Michelle Y. Walker, Reg. No. 53,903; January 2, 2004

RECEIVED  
CENTRAL FAX CENTER  
JAN 02 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Dreon *et al.*

Attorney Docket No.: 0125-UTL

Serial No 10/612,118

Art Group : unassigned

Filed: 7/2/2003

Examiner; unassigned

Title: Compositions and Methods For Reduction of Inflammatory Symptoms and/or Biomarkers in Female Subjects

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Transmitted herewith for filing in the above identified Application, under 37 C.F.R. 1.97, are an information Disclosure Statement and completed PTO Form 1449.

**1. Identification of Time of filing the Information Disclosure Statement and any Required Certification or Petition**

- ☐ The Information Disclosure Statement is being submitted: (a) within three (3) months of the filing date, or (b) before the mailing date of a first Office action on the merits. Therefore no fee is due or certification is required under 37 C.F.R. 1.97 (b).
- ☒ The Information Disclosure Statement is being submitted more than three (3) months after the filing date and after the mailing date of the first Office action on the merits, but before a final action under § 1.313 or a notice of allowance under § 1.311, whichever occurs first. The undersigned hereby certifies under 37 C.F.R. 1.97(e)(1) that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office on a counterpart foreign application not more than (3) months prior to the filing of the Information disclosure Statement. Therefore, no fee is due under 37 C.F.R. 1.97 (c).

Information Disclosure Statement  
Serial No: 10/612,118

Case 0125-UTL  
Page 2

## **2. Fee calculation and Deposit Account Authorization**

- ☐ The Information Disclosure Statement is being submitted more than three (3) months after the filing date and after the mailing date of the first Office action on the merits, but before a final action under § 1.313 or a notice of allowance under § 1.311, whichever occurs first, without certification under 37 C.F.R. 1.97(e). Therefore, *only if this entry is checked in the left margin*, the **\$ 180.00** fee set forth in §1.17 (p) is authorized below.

Applicant(s) hereby petition requesting consideration of the Information Disclosure Statement. *Therefore only if this entry is checked in the left margin*, the **\$180.00** petition fee set forth in § 117(i) is authorized below

- ☐ Please charge \$ \_\_\_\_\_ to Deposit Account No. 50-2247
- ☐ The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 50-2247. This is not however, an authorization to pay the issue fee. A duplicate of this document is enclosed.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



Michelle Y. Walker  
Agent for Applicants  
Registration No. 53,903

Galileo Pharmaceuticals, Inc.  
5301 Patrick Henry Drive  
Santa Clara, CA 95054  
Telephone No. (408) 654-5830 ex. 179

Date: January 2, 2004

<b>Form PTO-1449 (modified)</b> <b>Information Disclosure Statement by Applicant</b>  Sheet 1 of 1		ATTY. DOCKET NO. <b>0125-UTL</b>		SERIAL NO. <b>10/612,118</b>			
		APPLICANT <b>DREON et al.</b>					
		FILING DATE <b>7/2/2003</b>		GROUP			
<b>U.S. Patent Documents</b>							
Exam. Init.	Cite No.	Document Number	Name	Date MM-DD-YYYY	Addl. Ref.		
	A1	6,361,806	Allen	03-26-2002			
<b>Foreign Patent Documents</b>							
Exam. Init.	Cite No.	Office	Document Number	Name	Date MM-DD-YYYY	Addl. Ref.	T
<b>Other Documents</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
Exam. Init.	Cite No.						T
Examiner Signature				Date Considered			